Credence, Ceylinco provide modern cancer diagnosis
Credence and Ceylinco Healthcare, leaders in cancer diagnostics and
prevention, will provide state-of-the art prevention and screening
services using pioneering products designed and developed by Credence
Genomics, Sri Lanka's first and only pioneering next generation
sequencing facility.
The centre provides radiation treatment, chemotherapy, radioactive
iodine treatment regimens, along with post treatment, follow-up and
patient care.
The cooperation with Credence enables Ceylinco Healthcare to provide
diagnostics and prediction, which is 99.7% accurate. This will allow for
timely diagnosis and treatment.
Ceylinco Healthcare will also offer a test for precision medicine,
which again is another offering from Credence Genomics.
Other tests for post treatment patients are Bactfast and Fungifast
identifying all known fungus and bacteria known to man. |